Cross Cancer Institute ( Site 0201)

Edmonton, Alberta T6G 1Z2

0 studies enrolling now · 3 studies all time

What they study most

Colorectal Neoplasms, Head and Neck Neoplasms, Non-small Cell Lung Cancer (NSCLC)

Studies at this site

• Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) — Running, not enrolling
• Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) — Running, not enrolling
• Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) — Completed